Moderna has begun early-stage clinical trials of its HIV vaccine that employs messenger RNA, much like the company's successful COVID-19 vaccine, according to a press statement issued Thursday. The biotechnology company has collaborated with the nonprofit International AIDS Vaccine Initiative (IAVI) to develop the vaccine in the wake of the success of mRNA technology, which shaved years off typical vaccine development times and allowed for the emerging of COVID-19 vaccines in record time.